Expanded access to AVM0703 for solid tumors and blood cancers
Treatments studied
Part of Blood & lymphatic, Brain & nervous system, Cancer, Digestive system, Hormones & metabolism, Immune system & allergy, Kidney & urinary, Skin, Women’s health & pregnancy clinical trials.
This program provides access to an experimental drug called AVM0703, which may help the body's immune system fight cancer. It is for people with solid tumors or blood cancers who have run out of standard treatment options.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a solid tumor or a blood cancer.
- You are not currently receiving standard cancer treatments (like chemotherapy or radiation).
- You are not enrolled in another clinical trial for your cancer.
- You do not have serious medical conditions other than cancer (such as severe heart, lung, or kidney disease).
- This program is for patients who have limited or no other treatment options.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called MGC026 that targets a protein called B7-H3 on cancer cells, aiming to shrink or slow different advanced solid tumors. It is an early-phase study to find the right dose and check safety.
This trial tests a new drug, MRG006A, for people with advanced solid tumors, especially liver cancer. It aims to see if the drug is safe and effective by targeting a protein called GPC3 found on some cancer cells.
This trial provides access to an investigational drug called ABBV-706 for people who have no other standard treatment options. It aims to offer treatment when no other clinical trials are available.
This trial tests an investigational treatment called LM303 for people with advanced solid tumors like melanoma, lung cancer, or cervical cancer. It uses your own immune cells (called TILs) to fight the cancer, so you need a tumor large enough for cells to be collected.
This Phase 1/2 study tests AVM0703 in people ages 12+ with certain lymphoid cancers that have returned or not responded to treatment. It may help shrink the cancer or control it when other treatments have failed or are not possible.
This trial tests a new drug called ABL103 for people with advanced solid tumors that have not responded to other treatments. The goal is to see if it is safe and effective.
Hear when a new Glioblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.